Completed PHASE2 INTERVENTIONAL 1-arm NCT00053222

Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine

Sponsor: National Cancer Institute (NCI)

Updated 6 times since 2017 Last updated: Sep 4, 2013 Started: Feb 28, 2003 Primary completion: Jan 31, 2005 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00053222, this PHASE2 trial focuses on Pancreatic Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chicago, United States , Decatur, United States , Evanston, United States , Fort Wayne, United States , Harvey, United States , LaGrange, United States , Maywood, United States , Peoria, United States , Saint Joseph, United States , South Bend, United States and 1 more location